Skip to main content
SpringerLink
Log in

Adjuvant Therapy for Renal Cell Carcinoma: Targeted Approaches

  • Chapter
Renal Cell Carcinoma

  • 619 Accesses

Abstract

Renal cell carcinoma (RCC) remains a significant global health problem. Despite inroads in early detection, ̃50 %of patients either present with or develop metastatic disease during the natural history of their illness. There remains no consistent curative therapy for metastatic RCC. For patients with locally advanced disease, surgery remains the mainstay of curative therapy, but a significant number of patients still experience relapse, the risk of which is directly related to the presence of high-risk features at diagnosis. The search for effective adjuvant therapy to decrease the risk of relapse following surgery remains elusive. Therapeutic benefit in the setting of metastatic disease has not translated to success in the adjuvant therapy setting. Numerous clinical trials have examined the role of radiation therapy, immunotherapy, chemotherapy, vaccine therapy, and antiangiogenic therapies in the adjuvant setting. To date, none of these trials have demonstrated a significant benefit. Thus, the standard of care remains surveillance following surgical resection of locally advanced disease. Currently, clinical trials with the new targeted therapies developed for RCC are ongoing in the adjuvant setting. We anxiously await the results of these trials to determine whether they can significantly impact recurrence free and overall survival in the locally advanced setting following curative surgical resection.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 139.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Jemal, A., Murray, T., Ward, E., Samuels, A., Tiwari, R. C., Ghafoor, A., Feuer, E. J., and Thun, M. J. Cancer Statistics, 2005. CA Cancer J Clin, 55: 10–30, 2005.

    PubMed  Google Scholar 

  2. Pantuck, A. J., Zisman, A., and Belldegrun, A. S. The changing natural history of renal cell carcinoma. J Urol, 166: 1611–1623, 2001.

    PubMed  CAS  Google Scholar 

  3. Chow, W.-H., Devesa, S. S., Warren, J. L., and Fraumeni, J. F., Jr. Rising incidence of renal cell cancer in the United States. JAMA, 281: 1628–1631, 1999.

    PubMed  CAS  Google Scholar 

  4. Surveillance, E. a. E. R. P. available at www.seer.cancer.gov/csr/1975_2002. Vol. 2005, 1975–2002.

  5. Godley, P. A. and Taylor, M. Renal cell carcinoma. Curr Opin Oncol, 13: 199–203, 2001.

    PubMed  CAS  Google Scholar 

  6. Linehan, W. M., Walther, M. M., and Zbar, B. The genetic basis of cancer of the kidney. J Urol, 170: 2163–2172, 2003.

    PubMed  CAS  Google Scholar 

  7. Kim, W. Y. and Kaelin, W. G. Role of VHL gene mutation in human cancer. J Clin Oncol, 22: 4991–5004, 2004.

    PubMed  CAS  Google Scholar 

  8. Latif, F., Tory, K., Gnarra, J., Yao, M., Duh, F. M., Orcutt, M. L., Stackhouse, T., Kuzmin, I., Modi, W., Geil, L., et al. Identification of the von Hippel–Lindau disease tumor suppressor gene. Science, 260: 1317–1320, 1993.

    PubMed  CAS  Google Scholar 

  9. Dorai, T., Sawczuk, I. S., Pastorek, J., Wiernik, P. H., and Dutcher, J. P. The role of carbonic anhydrase IX overexpression in kidney cancer. Eur J Cancer, 41: 2935–2947, 2005.

    PubMed  CAS  Google Scholar 

  10. Linehan, W. M., Vasselli, J., Srinivasan, R., Walther, M. M., Merino, M., Choyke, P., Vocke, C., Schmidt, L., Isaacs, J. S., Glenn, G., Toro, J., Zbar, B., Bottaro, D., and Neckers, L. Genetic basis of cancer of the kidney: Disease-specific approaches to therapy. Clin Cancer Res, 10: 6282S–6289, 2004.

    PubMed  CAS  Google Scholar 

  11. Levy, D. A., Slaton, J. W., Swanson, D. A., and Dinney, C. P. Stage specific guidelines for surveillance after radical nephrectomy for local renal cell carcinoma. J Urol, 159: 1163–1167, 1998.

    PubMed  CAS  Google Scholar 

  12. Frank, I., Blute, M. L., Leibovich, B. C., Cheville, J. C., Lohse, C. M., and Zincke, H. Independent validation of the 2002 American Joint Committee on cancer primary tumor classification for renal cell carcinoma using a large, single institution cohort. J Urol, 173: 1889–1892, 2005.

    PubMed  Google Scholar 

  13. Patard, J.-J., Leray, E., Rioux-Leclercq, N., Cindolo, L., Ficarra, V. , Zisman, A., De La Taille, A., Tostain, J., Artibani, W., Abbou, C. C., Lobel, B., Guille, F., Chopin, D. K., Mulders, P. F. A., Wood, C. G., Swanson, D. A., Figlin, R. A., Belldegrun, A. S., and Pantuck, A. J. Prognostic value of histologic subtypes in renal cell carcinoma: A multicenter experience. J Clin Oncol, 23: 2763–2771, 2005.

    PubMed  Google Scholar 

  14. Lam, J. S., Leppert, J. T., Figlin, R. A., and Belldegrun, A. S. Role of molecular markers in the diagnosis and therapy of renal cell carcinoma. Urology, 66: 1–9, 2005.

    PubMed  Google Scholar 

  15. Zisman, A., Pantuck, A. J., Dorey, F., Said, J. W., Shvarts, O., Quintana, D., Gitlitz, B. J., deKernion, J. B., Figlin, R. A., and Belldegrun, A. S. Improved prognostication of renal cell carcinoma using an integrated staging system. J Clin Oncol, 19: 1649–1657, 2001.

    PubMed  CAS  Google Scholar 

  16. Frank, I., Blute, M. L., Cheville, J. C., Lohse, C. M., Weaver, A. L., and Zincke, H. An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score. J Urol, 168: 2395–2400, 2002.

    PubMed  Google Scholar 

  17. Kattan, M. W., Reuter, V., Motzer, R. J., Katz, J., and Russo, P. A postoperative prognostic nomogram for renal cell carcinoma. J Urol, 166: 63–67, 2001.

    PubMed  CAS  Google Scholar 

  18. Cindolo, L., de la Taille, A., Messina, G., Romis, L., Abbou, C. C., Altieri, V. , Rodriguez, A., and Patard, J. J. A preoperative clinical prognostic model for non-metastatic renal cell carcinoma. BJU Int, 92: 901–905, 2003.

    PubMed  CAS  Google Scholar 

  19. Yaycioglu, O., Roberts, W. W., Chan, T., Epstein, J. I., Marshall, F. F., and Kavoussi, L. R. Prognostic assessment of nonmetastatic renal cell carcinoma: a clinically based model. Urology, 58: 141–145, 2001.

    PubMed  CAS  Google Scholar 

  20. Fergany, A. F., Hafez, K. S., and Novick, A. C. Long-term results of nephron sparing surgery for localized renal cell carcinoma: 10-year followup. J Urol, 163: 442–445, 2000.

    PubMed  CAS  Google Scholar 

  21. Ono, Y., Hattori, R., Gotoh, M., Yoshino, Y. , Yoshikawa, Y., and Kamihira, O. Laparoscopic radical nephrectomy for renal cell carcinoma: the standard of care already? Curr Opin Urol, 15: 75–78, 2005.

    PubMed  Google Scholar 

  22. Mahnken, A. H., Gunther, R. W., and Tacke, J. Radiofrequency ablation of renal tumors. Eur Radiol, 14: 1449–1455, 2004.

    PubMed  Google Scholar 

  23. Spaliviero, M., Moinzadeh, A., and Gill, I. S. Laparoscopic cryotherapy for renal tumors. Technol Cancer Res Treat, 3: 177–180, 2004.

    PubMed  Google Scholar 

  24. Chawla, S. N., Crispen, P. L., Hanlon, A. L., Greenberg, R. E., Chen, D. Y. T., and Uzzo, R. G. The natural history of observed enhancing renal masses: Meta-analysis and review of the world literature. J Urol, 175: 425–431, 2006.

    PubMed  Google Scholar 

  25. Rabinovitch, R., Zelefsky, M., Gaynor, J., and Fuks, Z. Patterns of failure following surgical resection of renal cell carcinoma: implications for adjuvant local and systemic therapy. J Clin Oncol, 12: 206–212, 1994.

    PubMed  CAS  Google Scholar 

  26. Juusela, H., Malmio, K., Alfthan, O., and Oravisto, K. J. Preoperative irradiation in the treatment of renal adenocarcinoma. Scand J Urol Nephrol, 11: 277–281, 1977.

    PubMed  CAS  Google Scholar 

  27. Finney, R. The value of radiotherapy in the treatment of hypernephroma –a clinical trial. Br J Urol, 45: 258–269, 1973.

    PubMed  CAS  Google Scholar 

  28. Makarewicz, R., Zarzycka, M., Kulinska, G., and Windorbska, W. The value of postoperative radiotherapy in advanced renal cell cancer. Neoplasma, 45: 380–383, 1998.

    PubMed  CAS  Google Scholar 

  29. Master, V. A., Gottschalk, A. R., Kane, C., and Carroll, P. R. Management of isolated renal fossa recurrence following radical nephrectomy. J Urol, 174: 473–477;discussion 477, 2005.

    PubMed  Google Scholar 

  30. del Carmen, M. G., Eisner, B., Willet, C. G., and Fuller, A. F. Intraoperative radiation therapy in the management of gynecologic and genitourinary malignancies. Surg Oncol Clin N Am, 12: 1031–1042, 2003.

    PubMed  Google Scholar 

  31. Zielinski, H., Szmigielski, S., and Petrovich, Z. Comparison of preoperative embolization followed by radical nephrectomy with radical nephrectomy alone for renal cell carcinoma. Am J Clin Oncol, 23: 6–12, 2000.

    PubMed  CAS  Google Scholar 

  32. Sanchez-Ortiz, R. F., Tannir, N., Ahrar, K., and Wood, C. G. Spontaneous regression of pulmonary metastases from renal cell carcinoma after radio frequency ablation of primary tumor: an in situ tumor vaccine? J Urol, 170: 178–179, 2003.

    PubMed  Google Scholar 

  33. McCarty, K. S., Nichols, M., and McCarty, K. S. Progestins. In: D. W. Kufe, R. E. Pollock, R. R. Weichselbaum, R. C. Bast, T. S. Gansler, J. F. Holland, and E. Frei (eds.), Holland-Frei Cancer Medicine, 6th edition. Hamilton London: BC Decker, Inc., 2003.

    Google Scholar 

  34. Huggins, C., Stevens, R. E., and Hodges, C. V. Studies of prostatic cancer. II. The effects of castration on advanced carcinoma of the prostate gland. Arch Surg, 42: 209–223, 1941.

    Google Scholar 

  35. Joensuu, T. K., Nilsson, S., Holmberg, A. R., Marquez, M., Tenhunen, M., Saarto, T., and Joensuu, H. Phase I Trial on sms-D70 SOMATOSTATIN analogue in advanced prostate and renal cell cancer. Ann NY Acad Sci, 1028: 361–374, 2004.

    PubMed  CAS  Google Scholar 

  36. Keller, G., Schally, A. V. , Gaiser, T., Nagy, A., Baker, B., Halmos, G., and Engel, J. B. Receptors for luteinizing hormone releasing hormone expressed on human renal cell carcinomas can be used for targeted chemotherapy with cytotoxic luteinizing hormone releasing hormone analogues. Clin Cancer Res, 11: 5549–5557, 2005.

    PubMed  CAS  Google Scholar 

  37. Talon, I., Lindner, V. , Sourbier, C., Schordan, E., Rothhut, S., Barthelmebs, M., Lang, H., Helwig, J.-J., and Massfelder, T. Anti-tumor effect of parathyroid hormone-related protein neutralizing antibody in human renal cell carcinoma in vitro and in vivo. Carcinogenesis bgi203, 2005.

    Google Scholar 

  38. Ehrlich, P. ۢer den jetzigen Stand der Karzinomforschung. Ned Tijdschr Geneeskd, 5: 273–290, 1909.

    Google Scholar 

  39. Gleave, M. E., Elhilali, M., Fradet, Y. , Davis, I., Venner, P. , Saad, F., Klotz, L. H., Moore, M. J., Paton, V., Bajamonde, A., Bell, D., Ernst, S., Ramsey, E., Chin, J., Morales, A., Martins, H., and Sanders, C. The canadian urologic oncology group interferon gamma-1b compared with placebo in metastatic renal-cell carcinoma. N Engl J Med, 338: 1265–1271, 1998.

    PubMed  CAS  Google Scholar 

  40. Vogelzang, N. J., Priest, E. R., and Borden, L. Spontaneous regression of histologically proved pulmonary metastases from renal cell carcinoma: a case with 5-year followup. J Urol, 148: 1247–1248, 1992.

    PubMed  CAS  Google Scholar 

  41. Bleumer, I., Oosterwijk, E., De Mulder, P., and Mulders, P. F. Immunotherapy for renal cell carcinoma. Eur Urol, 44: 65–75, 2003.

    PubMed  CAS  Google Scholar 

  42. Prummer, O. Interferon-alpha antibodies in patients with renal cell carcinoma treated with recombinant interferon-alpha-2A in an adjuvant multicenter trial. The Delta-P Study Group. Cancer, 71: 1828–1834, 1993.

    PubMed  CAS  Google Scholar 

  43. Pizzocaro, G., Piva, L., Colavita, M., Ferri, S., Artusi, R., Boracchi, P., Parmiani, G., and Marubini, E. Interferon adjuvant to radical nephrectomy in robson stages ii and iii renal cell carcinoma: A Multicentric Randomized Study. J Clin Oncol, 19: 425–431, 2001.

    PubMed  CAS  Google Scholar 

  44. Messing, E. M., Manola, J., Wilding, G., Propert, K., Fleischmann, J., Crawford, E. D., Pontes, J. E., Hahn, R., and Trump, D. Phase III study of interferon alfa-NL as adjuvant treatment for resectable renal cell carcinoma: An Eastern Cooperative Oncology Group/Intergroup Trial. J Clin Oncol, 21: 1214–1222, 2003.

    PubMed  CAS  Google Scholar 

  45. Basting, R., Corvin, S., Handel, D., Hinke, A., and Schmidt, D. Adjuvant immunotherapy in renal cell carcinoma –comparison of interferon alpha treatment with an untreated control. Anticancer Res, 19: 1545–1548, 1999.

    PubMed  CAS  Google Scholar 

  46. Clark, J. I., Atkins, M. B., Urba, W. J., Creech, S., Figlin, R. A., Dutcher, J. P., Flaherty, L., Sosman, J. A., Logan, T. F., White, R., Weiss, G. R., Redman, B. G., Tretter, C. P. G., McDermott, D., Smith, J. W., Gordon, M. S., and Margolin, K. A. Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: A Cytokine Working Group Randomized Trial. J Clin Oncol, 21: 3133–3140, 2003.

    PubMed  CAS  Google Scholar 

  47. Jeon, S. H., Chang, S. G., and Kim, J. I. The role of adjuvant immunotherapy after radical nephrectomy and prognostic factors in pT3N0M0 renal cell carcinoma. Anticancer Res, 19: 5593–5597, 1999.

    PubMed  CAS  Google Scholar 

  48. Migliari, R., Muscas, G., Solinas, A., Melis, M., Ionta, M. T., Massidda, B., and Usai, E. Is there a role for adjuvant immunochemotherapy after radical nephrectomy in pT2–3N0M0 renal cell carcinoma? J Chemother, 7: 240–245, 1995.

    PubMed  CAS  Google Scholar 

  49. Hong, S. K., Kwak, C., and Lee, S. E. Adjuvant interleukin-2, interferon-alpha, and 5-fluor-ouracil immunochemotherapy after radical nephrectomy for locally advanced renal cell carcinoma. Urology, 66: 518–522, 2005.

    PubMed  Google Scholar 

  50. Atzpodien, J., Schmitt, E., Gertenbach, U., Fornara, P., Heynemann, H., Maskow, A., Ecke, M., Woltjen, H. H., Jentsch, H., Wieland, W., Wandert, T., and Reitz, M. Adjuvant treatment with interleukin-2- and interferon-alpha2a-based chemoimmunotherapy in renal cell carcinoma post tumour nephrectomy: results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). Br J Cancer, 92: 843–846, 2005.

    PubMed  CAS  Google Scholar 

  51. Mani, S., Todd, M., and Poo, W. J. Recombinant beta-interferon in the treatment of patients with metastatic renal cell carcinoma. Am J Clin Oncol, 19: 187–189, 1996.

    PubMed  CAS  Google Scholar 

  52. Decatris, M., Santhanam, S., and O'Byrne, K. Potential of interferon-alpha in solid tumours: part 1. BioDrugs, 16: 261–281, 2002.

    PubMed  CAS  Google Scholar 

  53. Quesada, J. R., Swanson, D. A., Trindade, A., and Gutterman, J. U. Renal cell carcinoma: antitumor effects of leukocyte interferon. Cancer Res, 43: 940–947, 1983.

    PubMed  CAS  Google Scholar 

  54. Hernberg, M., Pyrhonen, S., and Muhonen, T. Regimens with or without interferon-alpha as treatment for metastatic melanoma and renal cell carcinoma: an overview of randomized trials. J Immunother, 22: 145–154, 1999.

    PubMed  CAS  Google Scholar 

  55. Flanigan, R. C., Salmon, S. E., Blumenstein, B. A., Bearman, S. I., Roy, V., McGrath, P. C., Caton, J. R., Jr., Munshi, N., and Crawford, E. D. Nephrectomy followed by interferon Alfa-2b compared with interferon Alfa-2b alone for metastatic renal-cell cancer. N Engl J Med, 345: 1655–1659, 2001.

    PubMed  CAS  Google Scholar 

  56. Mickisch, G., Garin, A., van Poppel, H., de Prijck, L., and Sylvester, R. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomized trial. The Lancet, 358: 966–970, 2001.

    CAS  Google Scholar 

  57. Rosenberg, S., Mule, J., Spiess, P., Reichert, C., and Schwarz, S. Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2. J Exp Med, 161: 1169–1188, 1985.

    PubMed  CAS  Google Scholar 

  58. Fyfe, G., Fisher, R., Rosenberg, S., Sznol, M., Parkinson, D., and Louie, A. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol, 13: 688–696, 1995.

    PubMed  CAS  Google Scholar 

  59. Bleumer, I., Knuth, A., Oosterwijk, E., Hofmann, R., Varga, Z., Lamers, C., Kruit, W., Melchior, S., Mala, C., Ullrich, S., De Mulder, P., Mulders, P. F., and Beck, J. A phase II trial of chimeric monoclonal antibody G250 for advanced renal cell carcinoma patients. Br J Cancer, 90: 985–990, 2004.

    PubMed  CAS  Google Scholar 

  60. Negrier, S., Escudier, B., Lasset, C., Douillard, J.-Y., Savary, J., Chevreau, C., Ravaud, A., Mercatello, A., Peny, J., Mousseau, M., Philip, T., and Tursz, T. The Groupe Francais d-immunotherapie recombinant human interleukin-2, recombinant human interferon Alfa-2a, or both in metastatic renal-cell carcinoma. N Engl J Med, 338: 1272–1278, 1998.

    PubMed  CAS  Google Scholar 

  61. McDermott, D. F., Regan, M. M., Clark, J. I., Flaherty, L. E., Weiss, G. R., Logan, T. F., Kirkwood, J. M., Gordon, M. S., Sosman, J. A., Ernstoff, M. S., Tretter, C. P. G., Urba, W. J., Smith, J. W., Margolin, K. A., Mier, J. W., Gollob, J. A., Dutcher, J. P., and Atkins, M. B. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol, 23: 133–141, 2005.

    PubMed  CAS  Google Scholar 

  62. Motzer, R. J., Murphy, B. A., Bacik, J., Schwartz, L. H., Nanus, D. M., Mariani, T., Loehrer, P., Wilding, G., Fairclough, D. L., Cella, D., and Mazumdar, M. Phase III trial of interferon Alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma. J Clin Oncol, 18: 2972–2980, 2000.

    PubMed  CAS  Google Scholar 

  63. Hernberg, M., Virkkunen, P., Bono, P., Ahtinen, H., Maenpaa, H., and Joensuu, H. Interferon Alfa-2b three times daily and thalidomide in the treatment of metastatic renal cell carcinoma. J Clin Oncol, 21: 3770–3776, 2003.

    PubMed  CAS  Google Scholar 

  64. Hoffman, D. M., Gitlitz, B. J., Belldegrun, A., and Figlin, R. A. Adoptive cellular therapy. Semin Oncol, 27: 221–233, 2000.

    PubMed  CAS  Google Scholar 

  65. Grimm, E., Mazumder, A., Zhang, H., and Rosenberg, S. Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J Exp Med, 155: 1823–1841, 1982.

    PubMed  CAS  Google Scholar 

  66. Lafreniere, R. and Rosenberg, S. Adoptive immunotherapy of murine hepatic metastases with lymphokine activated killer (LAK) cells and recombinant interleukin 2 (RIL 2) can mediate the regression of both immunogenic and nonimmunogenic sarcomas and an adenocarcinoma. J Immunol, 135: 4273–4280, 1985.

    PubMed  CAS  Google Scholar 

  67. Rosenberg, S. A., Lotze, M. T., Muul, L. M., Leitman, S., Chang, A. E., Ettinghausen, S. E., Matory, Y. L., Skibber, J. M., Shiloni, E., Vetto, J. T., et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med, 313: 1485–1492, 1985.

    PubMed  CAS  Google Scholar 

  68. Osband, M. E., Lavin, P. T., Babayan, R. K., Graham, S., Lamm, D. L., Parker, B., Sawczuk, I., Ross, S., and Krane, R. J. Effect of autolymphocyte therapy on survival and quality of life in patients with metastatic renal-cell carcinoma. Lancet, 335: 994–998, 1990.

    PubMed  CAS  Google Scholar 

  69. Sawczuk, I., Graham, S. D., and Miesowicz, F. Randomized controlled trial of adjuvant therapy with ex vivo activated T cells (ALT) in T1–3a,b,c or T4N +M0 renal cell carcinoma. In: Proc Am Soc Clin Oncol 1997, pp. 326a.

    Google Scholar 

  70. McCune, C. S., O'Donnell, R. W., Marquis, D. M., and Sahasrabudhe, D. M. Renal cell carcinoma treated by vaccines for active specific immunotherapy: correlation of survival with skin testing by autologous tumor cells. Cancer Immunol Immunother, 32: 62–66, 1990.

    PubMed  CAS  Google Scholar 

  71. Repmann, R., Goldschmidt, A. J., and Richter, A. Adjuvant therapy of renal cell carcinoma patients with an autologous tumor cell lysate vaccine: a 5-year follow-up analysis. Anticancer Res, 23: 969–974, 2003.

    PubMed  CAS  Google Scholar 

  72. Repmann, R., Wagner, S., and Richter, A. Adjuvant therapy of renal cell carcinoma with active-specific-immunotherapy (ASI) using autologous tumor vaccine. Anticancer Res, 17: 2879–2882, 1997.

    PubMed  CAS  Google Scholar 

  73. 73 . Jocham, P. D., Richter, A., Hoffmann, L., Iwig, K., Fahlenkamp, P. D., Zakrzewski, G., Schmitt, E., Dannenberg, T., Lehmacher, P. W., von Wietersheim, J., and Doehn, C. Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial. The Lancet, 363: 594–599, 2004.

    CAS  Google Scholar 

  74. Galligioni, E., Quaia, M., Merlo, A., Carbone, A., Spada, A., Favaro, D., Santarosa, M., Sacco, C., and Talamini, R. Adjuvant immunotherapy treatment of renal carcinoma patients with autologous tumor cells and bacillus Calmette-Guerin: five-year results of a prospective randomized study. Cancer, 77: 2560–2566, 1996.

    PubMed  CAS  Google Scholar 

  75. Vieweg, J. and Dannull, J. Tumor vaccines: from gene therapy to dendritic cells–the emerging frontier. Urol Clin North Am, 30: 633–643, x, 2003.

    PubMed  Google Scholar 

  76. Marten, A., Flieger, D., Renoth, S., Weineck, S., Albers, P. , Compes, M., Schattker, B., Ziske, C., Engelhart, S., Hanfland, P., Krizek, L., Faber, C., von Ruecker, A., Müller S., Sauerbruch, T., and Schmidt-Wolf, I. Therapeutic vaccination against metastatic renal cell carcinoma by autologous dendritic cells: preclinical results and outcome of a first clinical phase I/II trial. Cancer Immunol Immunother, 51: 637–644, 2002.

    PubMed  Google Scholar 

  77. Srivastava, P. Roles of heat-shock proteins in innate and adaptive immunity. Nat Rev Immunol, 2: 185–194, 2002.

    PubMed  CAS  Google Scholar 

  78. Steffens, M. G., Boerman, O. C., de Mulder, P. H., Oyen, W. J., Buijs, W. C., Witjes, J. A., van den Broek, W. J., Oosterwijk-Wakka, J. C., Debruyne, F. M., Corstens, F. H., and Oosterwijk, E. Phase I radioimmunotherapy of metastatic renal cell carcinoma with 131I-labeled chimeric monoclonal antibody G250. Clin Cancer Res, 5: 3268s–3274s, 1999.

    PubMed  CAS  Google Scholar 

  79. Bleumer, I., Oosterwijk, E., Oosterwijk-Wakka, J. C., Voller, M. C. W., Melchior, S., Warnaar, S. O., Mala, C., Beck, J., and Mulders, P. F. A. A clinical trial with chimeric monoclonal antibody WX-G250 and low dose interleukin-2 pulsing scheme for advanced renal cell carcinoma. J Urol, 175: 57–62, 2006.

    PubMed  CAS  Google Scholar 

  80. Gordon, M. S., Margolin, K., Talpaz, M., Sledge, G. W., Jr, Holmgren, E., Benjamin, R., Stalter, S., Shak, S., and Adelman, D. C. Phase i safety and pharmacokinetic study of recom-binant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol, 19: 843–850, 2001.

    PubMed  CAS  Google Scholar 

  81. Yang, J. C., Haworth, L., Sherry, R. M., Hwu, P., Schwartzentruber, D. J., Topalian, S. L., Steinberg, S. M., Chen, H. X., and Rosenberg, S. A. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med, 349: 427–434, 2003.

    PubMed  CAS  Google Scholar 

  82. Elaraj, D. M., White, D. E., Steinberg, S. M., Haworth, L., Rosenberg, S. A., and Yang, J. C. A pilot study of antiangiogenic therapy with bevacizumab and thalidomide in patients with metastatic renal cell carcinoma. J Immunother, 27: 259–264, 2004.

    PubMed  CAS  Google Scholar 

  83. Spigel, D., Hainsworth, J., Sosman, J., Raefsky, E., Meluch, A., Edwards, D., Horowitz, P., Thomas, K., Yost, K., Stagg, M., and Greco, A. Bevacizumab and erlotinib in the treatment of patients with metastatic renal carcinoma (RCC): Update of a phase II multicenter trial. J Clin Oncol, 23(suppl): 387s (abstract 4540), 2005.

    Google Scholar 

  84. Hainsworth, J. D., Sosman, J. A., Spigel, D. R., Edwards, D. L., Baughman, C., and Greco, A. Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlo-tinib. J Clin Oncol, 23: 7889–7896, 2005.

    PubMed  CAS  Google Scholar 

  85. Oosterwijk, E., Ruiter, D. J., Hoedemaeker, P. J., Pauwels, E. K., Jonas, U., Zwartendijk, J., and Warnaar, S. O. Monoclonal antibody G 250 recognizes a determinant present in renal-cell carcinoma and absent from normal kidney. Int J Cancer, 38: 489–494, 1986.

    PubMed  CAS  Google Scholar 

  86. Liu, Z., Smyth, F. E., Renner, C., Lee, F.-T., Oosterwijk, E., and Scott, A. M. Anti-renal cell carcinoma chimeric antibody G250: cytokine enhancement of in vitro antibody-dependent cellular cytotoxicity. Cancer Immunol Immunother, 51: 171–177, 2002.

    PubMed  CAS  Google Scholar 

  87. Divgi, C. R., O'Donoghue, J. A., Welt, S., O'Neel, J., Finn, R., Motzer, R. J., Jungbluth, A., Hoffman, E., Ritter, G., Larson, S. M., and Old, L. J. Phase I clinical trial with fractionated radioimmunotherapy using 131I-labeled chimeric G250 in metastatic renal cancer. J Nucl Med, 45: 1412–1421, 2004.

    PubMed  CAS  Google Scholar 

  88. Brouwers, A. H., Mulders, P. F. A., de Mulder, P. H. M., van den Broek, W. J. M., Buijs, W. C. A. M., Mala, C., Joosten, F. B. M., Oosterwijk, E., Boerman, O. C., Corstens, F. H. M., and Oyen, W. J. G. Lack of efficacy of two consecutive treatments of radioimmunotherapy with 131I-cG250 in patients with metastasized clear cell renal cell carcinoma. J Clin Oncol, 23: 6540–6548, 2005.

    PubMed  CAS  Google Scholar 

  89. Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., Ferrara, N., Fyfe, G., Rogers, B., Ross, R., and Kabbinavar, F. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med, 350: 2335–2342, 2004.

    PubMed  CAS  Google Scholar 

  90. Yang, J. C. Bevacizumab for patients with metastatic renal cancer: An update. Clin Cancer Res, 10: 6367S–6370, 2004.

    PubMed  CAS  Google Scholar 

  91. Yagoda, A., Abi-Rached, B., and Petrylak, D. Chemotherapy for advanced renal-cell carcinoma: 1983–1993. Semin Oncol, 22: 42–60, 1995.

    PubMed  CAS  Google Scholar 

  92. Masuda, F., Nakada, J., Kondo, I., and Furuta, N. Adjuvant chemotherapy with vinblastine, adri-amycin, and UFT for renal-cell carcinoma. Cancer Chemother Pharmacol, 30: 477–479, 1992.

    PubMed  CAS  Google Scholar 

  93. Naito, S., Kumazawa, J., Omoto, T., Iguchi, A., Sagiyama, K., Osada, Y., and Hiratsuka, Y. Postoperative UFT adjuvant and the risk factors for recurrence in renal cell carcinoma: a long-term follow-up study. Kyushu University Urological Oncology Group. Int J Urol, 4: 8–12, 1997.

    PubMed  CAS  Google Scholar 

  94. D'Amato, R., Loughnan, M., Flynn, E., and Folkman, J. Thalidomide is an inhibitor of ang-iogenesis. PNAS, 91: 4082–4085, 1994.

    PubMed  Google Scholar 

  95. Eisen, T., Boshoff, C., Mak, I., Sapunar, F., Vaughan, M. M., Pyle, L., Johnston, S. R., Ahern, R., Smith, I. E., and Gore, M. E. Continuous low dose thalidomide: A phase II study in advanced melanoma, renal cell, ovarian and breast cancer. Br J Cancer, 82: 812–817, 2000.

    PubMed  CAS  Google Scholar 

  96. Danai, D. D., Papandreou, C. N., Thall, P. F., Wang, X., Perez, C., Oliva, R., Pagliaro, L., and Amato, R. A pilot study of thalidomide in patients with progressive metastatic renal cell carcinoma. Cancer, 95: 758–765, 2002.

    Google Scholar 

  97. Minor, D. R., Monroe, D., Damico, L. A., Meng, G., Suryadevara, U., and Elias, L. A phase II study of thalidomide in advanced metastatic renal cell carcinoma. Invest New Drugs, 20: 389–393, 2002.

    PubMed  CAS  Google Scholar 

  98. Motzer, R. J., Berg, W., Ginsberg, M., Russo, P., Vuky, J., Yu, R., Bacik, J., and Mazumdar, M. Phase II trial of thalidomide for patients with advanced renal cell carcinoma. J Clin Oncol, 20: 302–306, 2002.

    PubMed  CAS  Google Scholar 

  99. Stebbing, J., Benson, C., Eisen, T., Pyle, L., Smalley, K., Bridle, H., Mak, I., Sapunar, F., Ahern, R., and Gore, M. E. The treatment of advanced renal cell cancer with high-dose oral thalidomide. Br J Cancer, 85: 953–958, 2001.

    PubMed  CAS  Google Scholar 

  100. Gordon, M. S. Novel antiangiogenic therapies for renal cell cancer. Clin Cancer Res, 10: 6377S–6381S, 2004.

    PubMed  CAS  Google Scholar 

  101. Wood, C. G. Personal Communication. 2006.

    Google Scholar 

  102. O'Brien, S. G., Guilhot, F., Larson, R. A., Gathmann, I., Baccarani, M., Cervantes, F., Cornelissen, J. J., Fischer, T., Hochhaus, A., Hughes, T., Lechner, K., Nielsen, J. L., Rousselot, P., Reiffers, J., Saglio, G., Shepherd, J., Simonsson, B., Gratwohl, A., Goldman, J. M., Kantarjian, H., Taylor, K., Verhoef, G., Bolton, A. E., Capdeville, R., and Druker, B. J. The IRIS investigators imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med, 348: 994–1004, 2003.

    PubMed  Google Scholar 

  103. Awada, A., Hendlisz, A., Gil, T., Bartholomeus, S., Mano, M., de Valeriola, D., Strumberg, D., Brendel, E., Haase, C. G., Schwartz, B., and Piccart, M. Phase I safety and pharmacoki-netics of BAY 43–9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours. Br J Cancer, 92: 1855–1861, 2005.

    PubMed  CAS  Google Scholar 

  104. Ahmad, T. and Eisen, T. Kinase inhibition with BAY 43–9006 in renal cell carcinoma. Clin Cancer Res, 10: 6388S–6392, 2004.

    PubMed  CAS  Google Scholar 

  105. Faivre, S., Delbaldo, C., Vera, K., Robert, C., Lozahic, S., Lassau, N., Bello, C., Deprimo, S., Brega, N., Massimini, G., Armand, J.-P., Scigalla, P., and Raymond, E. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol, 24: 25–35, 2006.

    PubMed  CAS  Google Scholar 

  106. Motzer, R. J., Michaelson, M. D., Redman, B. G., Hudes, G. R., Wilding, G., Figlin, R. A., Ginsberg, M. S., Kim, S. T., Baum, C. M., DePrimo, S. E., Li, J. Z., Bello, C. L., Theuer, C. P., George, D. J., and Rini, B. I. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol, 24: 16–24, 2006.

    PubMed  CAS  Google Scholar 

  107. Raymond, E., Alexandre, J., Faivre, S., Vera, K., Materman, E., Boni, J., Leister, C., Korth-Bradley, J., Hanauske, A., and Armand, J.-P. Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. J Clin Oncol, 22: 2336–2347, 2004.

    PubMed  CAS  Google Scholar 

  108. Atkins, M. B., Hidalgo, M., Stadler, W. M., Logan, T. F., Dutcher, J. P., Hudes, G. R., Park, Y. , Liou, S.-H., Marshall, B., Boni, J. P., Dukart, G., and Sherman, M. L. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol, 22: 909–918, 2004.

    PubMed  CAS  Google Scholar 

  109. Oka, H., Chatani, Y., Hoshino, R., Ogawa, O., Kakehi, Y., Terachi, T., Okada, Y. , Kawaichi, M., Kohno, M., and Yoshida, O. Constitutive activation of mitogen-activated protein (MAP) kinases in human renal cell carcinoma. Cancer Res, 55: 4182–4187, 1995.

    PubMed  CAS  Google Scholar 

  110. Clark, J. W., Eder, J. P., Ryan, D., Lathia, C., and Lenz, H.-J. Safety and pharmacokinetics of the dual action raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43–9006, in patients with advanced, refractory solid tumors. Clin Cancer Res, 11: 5472–5480, 2005.

    PubMed  CAS  Google Scholar 

  111. Strumberg, D., Richly, H., Hilger, R. A., Schleucher, N., Korfee, S., Tewes, M., Faghih, M., Brendel, E., Voliotis, D., Haase, C. G., Schwartz, B., Awada, A., Voigtmann, R., Scheulen, M. E., and Seeber, S. Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43–9006 in patients with advanced refractory solid tumors. J Clin Oncol, 23: 965–972, 2005.

    PubMed  CAS  Google Scholar 

  112. Sakamoto, K. M. Su-11248 Sugen. Curr Opin Investig Drugs, 5: 1329–1339, 2004.

    PubMed  CAS  Google Scholar 

  113. Galanis, E., Buckner, J. C., Maurer, M. J., Kreisberg, J. I., Ballman, K., Boni, J., Peralba, J. M., Jenkins, R. B., Dakhil, S. R., Morton, R. F., Jaeckle, K. A., Scheithauer, B. W., Dancey, J., Hidalgo, M., and Walsh, D. J. Phase II trial of temsirolimus (CCI-779) in recurrent gliob-lastoma multiforme: A North Central Cancer Treatment Group Study. J Clin Oncol, 23: 5294–5304, 2005.

    PubMed  CAS  Google Scholar 

  114. Chan, S., Scheulen, M. E., Johnston, S., Mross, K., Cardoso, F., Dittrich, C., Eiermann, W., Hess, D., Morant, R., Semiglazov, V. , Borner, M., Salzberg, M., Ostapenko, V. , Illiger, H.-J., Behringer, D., Bardy-Bouxin, N., Boni, J., Kong, S., Cincotta, M., and Moore, L. Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer. J Clin Oncol, 23: 5314–5322, 2005.

    PubMed  CAS  Google Scholar 

  115. Witzig, T. E., Geyer, S. M., Ghobrial, I., Inwards, D. J., Fonseca, R., Kurtin, P., Ansell, S. M., Luyun, R., Flynn, P. J., Morton, R. F., Dakhil, S. R., Gross, H., and Kaufmann, S. H. Phase II Trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J Clin Oncol, 23: 5347–5356, 2005.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Wake Forest University School of Medicine, Winston-Salem, NC

    A. Karim Kadar

  2. Department of Urology, MD Anderson Cancer Center, University of Texas, TX, Houston, 77030

    Christopher G. Wood

Authors
  1. A. Karim Kadar
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Christopher G. Wood
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Christopher G. Wood .

Editor information

Editors and Affiliations

  1. Cleveland Clinic Foundation, Cleveland Clinic Taussig Cancer Center and CCF Lerner College of Medicine of CWRU, Cleveland, OH

    Ronald M. Bukowski

  2. Division of Medical Oncology & Experimental Therapeutics, City of Hope National Medical, Center/Beckman Research Institute, Duarte, CA

    Robert A. Figlin

  3. Memorial-Sloan Kettering Cancer Center, New York, NY

    Robert J. Motzer

Rights and permissions

Reprints and permissions

Copyright information

© 2009 Humana Press, a part of Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Kadar, A.K., Wood, C.G. (2009). Adjuvant Therapy for Renal Cell Carcinoma: Targeted Approaches. In: Bukowski, R.M., Figlin, R.A., Motzer, R.J. (eds) Renal Cell Carcinoma. Humana Press. https://doi.org/10.1007/978-1-59745-332-5_25

Download citation

  • DOI: https://doi.org/10.1007/978-1-59745-332-5_25

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-58829-737-2

  • Online ISBN: 978-1-59745-332-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation